DVA · Davita Inc.

$239.50 +3.19 (+1.35%)

Market Cap

$15.17B

64.20M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$13.64B +6.5%

FY2025

Net Income

$746.8M -20.2%

FY2025

Operating Margin

14.98% -1.3pp

FY2025

Diluted EPS

$9.84 -8.3%

FY2025

Operating Cash Flow

$1.89B -6.7%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	+5.5%	+3.4%	—	—	$13.84B	$13.64B	$12.82B	$12.14B	$11.61B	$11.62B	$11.55B	$11.39B	$11.4B	$10.88B	$10.71B	—	—	—	—	—	—	—	—	—
General & Administrative	+7.3%	+6.1%	+5.0%	—	$1.72B	$1.67B	$1.54B	$1.47B	$1.36B	$1.2B	$1.25B	$1.1B	$1.14B	$1.06B	$1.07B	$1.03B	$1.26B	$1.18B	$889.88M	$684.72M	$571.83M	$531.53M	$508.24M	$491.24M
Amortization of Intangibles	-14.8%	-12.5%	-9.5%	—	—	$7.1M	$7.46M	$8.97M	$11.47M	$12.86M	$13.81M	$14.25M	$16.24M	$15.78M	$14.55M	$19.19M	$167.96M	$160.96M	$47.49M	$21.59M	$19.09M	$565K	$1.42M	—
Depreciation & Amortization	-0.6%	+2.8%	+4.8%	—	$709.63M	$708.25M	$716.4M	$736.47M	$721.13M	$667.76M	$616.63M	$600.91M	$574.8M	$544.13M	$494.95M	$444.72M	$428.31M	$373.11M	$299.81M	$247.97M	$217.79M	$213.66M	$201.01M	$193.47M
Total Costs & Expenses	+4.1%	+3.3%	+2.7%	—	$11.75B	$11.6B	$10.73B	$10.54B	$10.27B	$9.82B	$9.86B	$9.75B	$9.88B	$9.06B	$8.68B	$8.85B	$10.98B	$10.21B	$6.89B	$5.58B	$5.23B	$5B	$4.79B	$4.36B
Operating Income	+15.1%	+3.8%	+6.0%	—	$2.09B	$2.04B	$2.09B	$1.6B	$1.34B	$1.8B	$1.69B	$1.64B	$1.53B	$1.81B	$2.03B	$1.14B	$1.82B	$1.55B	$1.3B	$1.15B	$993.81M	$939.63M	$869.1M	$908.91M
Operating Margin	—	—	—	—	—	14.98%	16.31%	13.2%	11.53%	15.47%	14.67%	14.43%	13.38%	16.67%	18.96%	—	—	—	—	—	—	—	—	—
EBITDA	+10.1%	+3.6%	+5.7%	—	$2.8B	$2.75B	$2.81B	$2.34B	$2.06B	$2.47B	$2.31B	$2.24B	$2.1B	$2.36B	$2.52B	$1.58B	$2.24B	$1.92B	$1.6B	$1.4B	$1.21B	$1.15B	$1.07B	$1.1B
Other Non-Operating Income	—	—	—	—	-$80.67M	-$102.69M	-$69.81M	-$19.18M	-$15.77M	$6.38M	$16.76M	$29.35M	$10.09M	$17.67M	$7.51M	$8.07M	$2.37M	$4.79M	$3.74M	$2.98M	—	—	—	—
Equity in Earnings of Unconsolidated Entities	+7.6%	+4.2%	+9.0%	—	$35.74M	$33M	$26.19M	$27.86M	$26.52M	$26.94M	$26.92M	$12.68M	-$4.48M	-$8.64M	$16.87M	$13.92M	$23.23M	$34.56M	$16.38M	$8.78M	$9M	$2.44M	$796K	$1.22M
Pretax Income	+11.7%	+0.4%	+6.9%	—	$1.4B	$1.35B	$1.53B	$1.18B	$966.28M	$1.52B	$1.32B	$1.2B	$1.05B	$1.4B	$1.62B	$688.39M	$1.31B	$1.12B	$1B	$916.61M	$741.24M	$757.58M	$656.79M	$674.22M
Income Tax	+14.0%	-1.4%	+3.5%	—	$305.19M	$293.11M	$279.66M	$220.12M	$198.09M	$306.73M	$313.93M	$279.63M	$258.4M	$323.86M	$431.76M	$207.51M	$446.34M	$381.01M	$359.85M	$325.29M	$258.87M	$278.21M	$235.47M	$245.58M
Net Income	+10.0%	-0.7%	+10.7%	—	$781.42M	$746.8M	$936.34M	$691.54M	$560.4M	$978.45M	$773.64M	$810.98M	$159.39M	$663.62M	$879.87M	$269.73M	$723.11M	$633.45M	$536.02M	$478M	$405.68M	$422.68M	$374.16M	$381.78M
Net Margin	—	—	—	—	—	5.47%	7.31%	5.7%	4.83%	8.42%	6.7%	7.12%	1.4%	6.1%	8.22%	—	—	—	—	—	—	—	—	—
Net Income Attributable to Noncontrolling Interests	+14.5%	+8.5%	+7.7%	—	$340.12M	$331.91M	$314.4M	$265.44M	$221.24M	$233.31M	$221.04M	$210.31M	$173.65M	$166.94M	$153.21M	$157.68M	$140.22M	$123.76M	$105.22M	$95.39M	$78.54M	$57.08M	$47.16M	$46.87M
Net Income Available to Common Stockholders	+11.6%	+13.0%	—	—	—	—	—	—	—	—	—	—	—	—	$879.87M	$269.73M	$723.11M	$633.45M	$536.02M	$478.34M	$405.62M	$422.42M	$374.16M	—
Comprehensive Income	+14.0%	+4.4%	+14.8%	—	$921.43M	$934.82M	$677.63M	$708.64M	$630.46M	$905.36M	$754.99M	$798.41M	$119.6M	$766.5M	$850.06M	$234.92M	$700.74M	$646.1M	$540.2M	$458.01M	$411.73M	$431.48M	—	—
EPS (Basic) USD/shares	+18.6%	+9.3%	+23.0%	—	—	$10.06	$11.02	$7.62	$6.03	$9.30	$6.46	$5.29	$0.93	$3.52	$4.36	$1.27	$3.41	$3.02	$2.79	$2.53	$4.00	$4.08	$3.56	$3.61
EPS (Diluted) USD/shares	+18.9%	+9.3%	+22.9%	$14.10 – $15.20*	—	$9.84^G	$10.73	$7.42	$5.85	$8.90	$6.31	$5.27	$0.92	$3.47	$4.29	$1.25	$3.33	$2.95	$2.74	$2.48	$3.94	$4.06	$3.53	$3.55
Shares Outstanding (Basic Avg) shares	-7.2%	-9.1%	-10.0%	—	—	74.23M	84.99M	90.79M	92.99M	105.23M	119.8M	153.18M	170.79M	188.63M	201.64M	211.87M	212.3M	209.94M	192.04M	189.32M	101.5M	103.6M	105.15M	105.89M
Shares Outstanding (Diluted Avg) shares	-7.5%	-9.2%	-9.9%	—	—	75.89M	87.27M	93.18M	95.83M	109.95M	122.62M	153.81M	172.37M	191.35M	204.9M	216.25M	216.93M	214.76M	195.94M	193.06M	103.06M	104.17M	105.94M	107.42M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $14.1B in buybacks, $0 in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 1.56×

EV/EBIT

—

Peer median 22.45×

P/E (TTM)

22.06×

Peer median 18.43×

Peer medians compare against the 27 similar-size Medical Care Facilities companies (of 57 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
US Dialysis and Related Lab Services with Intersegment	$11,792,944,000	$11,390,717,000	$10,936,998,000	$10,599,809,000	—	—	—	—
All Other Segments	$1,911,083,000	$1,496,580,000	$1,291,371,000	$1,097,120,000	$1,042,630,000	$1,035,955,000	$957,898,000	$1,161,852,000
Other Operating Segments With Intersegment	—	$1,510,490,000	$1,299,223,000	$1,101,326,000	—	—	—	—
US Dialysis and Related Lab Services	—	$11,318,970,000	$10,848,776,000	$10,512,774,000	$10,576,167,000	$10,514,649,000	$10,430,581,000	$10,242,999,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
US Dialysis and Related Lab Services	$2,084,233,000	$2,121,007,000	$1,774,578,000	$1,565,310,000	$1,974,988,000	$1,917,604,000	$1,924,826,000	$1,709,721,000
All Other Segments	$92,379,000	$82,657,000	-$8,747,000	-$96,579,000	-$66,003,000	-$76,261,000	-$189,174,000	-$93,789,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
All Other Segments	4.8%	5.5%	-0.7%	-8.8%	-6.3%	-7.4%	-19.7%	-8.1%
US Dialysis and Related Lab Services	—	18.7%	16.4%	14.9%	18.7%	18.2%	18.5%	16.7%

Key facts CIK 927066 CUSIP 23918K108 13F (30d) 171 filings 146 filers Visit website Investor relations